Cetuximab works by binding to the extracellular domain of the EGFR. This prevents the receptor from being activated by its natural ligands, such as EGF and TGF-α. The inhibition of EGFR signaling pathways leads to reduced proliferation, increased apoptosis, and decreased angiogenesis in cancer cells.
